June 16, 2014

Dr. Margaret Chan  
Director General  
World Health Organization  
Geneva

Dear Dr. Chan,

We, the 122 signatories to this letter, are writing to express our support for WHO’s evidence-based approach to determine the best way forward for public health to respond to Electronic Nicotine Delivery Systems (ENDS), as expressed in WHO’s June 3, 2014 statement.1

Recently, media attention was focused on a statement by a group of “specialists in nicotine science and public health policy.”2 Unfortunately, the statement makes several assertions about ENDS’ marketing, emissions, harms, and use that are either contradicted by available evidence or for which no evidence is currently available. (Indeed, the statement does not cite a single scientific study.)

The statement also included several policy recommendations, including effectively exempting ENDS from FCTC Articles 8 and 13 and ignoring Article 5.3.

It is fundamental that WHO and other public health authorities not buy into the tobacco industry's well-documented strategy of presenting itself as a "partner."3 If the tobacco industry was committed to reducing the harm caused by tobacco use, it would announce target dates to stop manufacturing, marketing and selling its "more harmful" products rather than simply adding e-cigarettes to its product mix and rapidly taking over the e-cigarette market.4⁻⁵ It would also immediately desist from its aggressive opposition to tobacco control policies such as tax increases, graphic health warnings and plain packaging.

By moving into the e-cigarette market, the tobacco industry is only maintaining its predatory practices and increasing profits. As stated in the guidelines for Article 5.3 of the WHO FCTC, there is a “fundamental and irreconcilable conflict of interest” between the tobacco industry’s interests and public health’s interests.”⁶

Public health embraced cigarette filters and “low tar” cigarettes as harm reduction strategies before manufacturers provided evidence and at a time when the manufacturers were well aware that these technologies did not actually reduce harm but were designed to promote cigarette sales by reassuring a concerned public that the new products were safer.7⁻⁸ The negative consequences of these acts remain in cancer and heart disease hospital wards throughout the world. Ignoring the link between ENDS and the tobacco industry is overlooking
the WHO FCTC Parties’ legal obligation to protect government policies against tobacco industry interference.

The aggressive marketing and promotion of e-cigarettes to youth is well-documented\(^9\)-\(^{12}\) and evidence from the US\(^{13,14}\) and Korea\(^{15}\) shows rapid growth in youth e-cigarette use, including disturbing rates among youth who have never smoked a cigarette. One e-cigarette manufacturer warns parents that “kids may be particularly vulnerable” to the flavoring in its products.\(^{16}\)

Manufacturers of ENDS are making a range of false and unproven claims,\(^{17,18,19}\) misleading the public into thinking these products are harmless (they are not) and effective cessation aids (unknown). Most ENDS users are "dual users" who continue to smoke cigarettes.\(^{20}\) Reviews of evidence about reducing smoking (instead of quitting) show that dual users are unlikely to see any health benefit in terms of cardiovascular disease.\(^{21,22}\) Population studies of all smokers consistently show that smokers who use ENDS are less likely to stop smoking.\(^{23,24,25,26,27,28}\)

The evidence is insufficient to accept the assertions that ENDS are effective as a smoking cessation device. There is a single randomized controlled trial of early generation e-cigarettes that found no difference between ENDS delivered directly to experimental subjects compared with mailing subjects a voucher that they could take to a pharmacy to obtain nicotine replacement therapy.\(^{29}\) One population-based cross-sectional study found that highly motivated smokers using ENDS to quit were less likely to be still smoking than smokers making unassisted quit attempts with over-the-counter NRT.\(^{30}\) However, this cross-sectional study\(^{31}\) showed a point prevalence of 80% of smokers using ENDS in a cessation attempt having failed, compared to 84.6% of those who tried to quit unassisted. Significantly, the former study is biased against conventional therapy (because of the additional barrier to getting the NRT) and the latter did not report a comparison with well-supervised approved cessation therapies.

There is already good evidence that ENDS emissions release several toxic substances into the environment that cause harm to health. These substances include ultrafine particles, propylene glycol, tobacco-specific nitrosamines; nicotine; volatile organic compounds (VOCs), and carcinogens and reproductive toxins, including benzene, lead, nickel, and others.\(^{32,33,34,35,36,37,38,39,40}\) Proposals to allow ENDS use in indoor spaces like workplaces, bars and transportation could see significant exposure to these substances.

It is important to note that nicotine itself is not harmless, which is why strict regulatory measures are in place to control the marketing of Nicotine Replacement Therapy for smoking cessation. The 2014 U.S. Surgeon General Report includes an extensive review of acute and long-term effects of nicotine exposure. It concludes, among other things, that nicotine exposure has adverse effects on fetal growth and development, including fetal brain development.\(^{41}\) The manufacturer of one electronic cigarette in the U.S. acknowledges in its product labeling that nicotine is not harmless.\(^{42}\) Acute poisoning from nicotine is well established, and there has been an increase in documented cases of children being accidentally poisoned by ingesting the liquid content of ENDS cartridges.\(^{43}\)
Remaining unregulated, risk profiles and potential harms these products may pose to the public are unknown. The absence of detailed evidence on adverse health effects is not evidence that no effect exists. Rather, insufficient time has elapsed to determine what effects exist and their magnitude on a population level.

Manufacturers have not secured regulatory approval for claims that ENDS are effective products for smoking cessation or harm reduction from regulatory authorities in any country. From a population perspective, it is important to know what new risks a consumer product may introduce in the market.

We applaud WHO’s commitment to listen to the experience from Member States that have successfully implemented tobacco control and regulated sales, marketing and use of ENDS. Implementation of the WHO FCTC by its 178 parties demonstrates great progress in decreasing the harm caused by tobacco use and decreasing the burden from NCDs.

There is evidence of success from many countries, including Australia, Brazil and Turkey. The former prohibits import and sales of cartridges containing nicotine, the latter two banned import, sales and marketing of e-cigarettes until, and unless, manufacturers present safety information.

Both scientific evidence and best practices are available to support a regulatory framework that will best prevent initiation of use among youth and other non-tobacco users, protect bystanders in public areas from involuntary exposure, regulate marketing, and prohibit unsubstantiated claims.

Such a regulatory framework would require manufacturers to present safety and efficacy data. In this case, the use of these products as cessation aids (if the evidence supports such use) would operate under the supervision of a health authority that could control manufacturers’ claims, impose health warnings about risks, require disclosure of ingredients and safety data and regulate product engineering as well as mandate surveillance.

This is the path that the WHO has been pursuing and encouraging. We urge you to continue doing so.
Professor Kristina Alexanderson  
Stockholm  
Sweden  

Peter Allebeck  
Professor of Social Medicine  
Department of Public Health Sciences  
Karolinska Institute  
Stockholm  
Sweden  

Alberto Jose de Araujo MD, PhD  
Nucleus of Research on Tobacco Treatment  
Thorax Diseases Institute  
Federal University of Rio de Janeiro  
Brazil  

Dr. Monika Arora PhD, MSc (PH), MSc (CD)  
Director, Health Promotion &  
Adjunct Associate Professor  
Public Health Foundation of India &  
Executive Director  
HRIDAY (Health Related Information Dissemination Amongst Youth)  
India  

Carlos M. Artundo MD  
Director  
EASP, Andalusian School of Public Health  
Spain  

Professor John Ashton CBE  
President, UK Faculty of Public Health  
United Kingdom  

Dr Ozen Asut  
Associate Professor of Public Health  
Former President of the Turkish Medical Association  
Former member of Hacettepe University Medical Faculty  
Editor, "Continuing Medical Education Journal" of the Turkish Medical Association  
Turkey
Professor Rifat Atun
Professor of Global Health Systems
Director, Global Health Systems Cluster
Department of Global Health and Population
Harvard School of Public Health
Harvard University
USA

Dileep G Bal MD  MS MPH
Founder/Director of California's Tobacco Control Program (1981 to 2005)
Former American Cancer Society President (2000-2001)
Kauai District Health Officer,
Special Advisor to the Director on Tobacco and Chronic Disease,
Hawai‘i State Department of Health.
Clinical Professor, Hawai‘i Cancer Center and College of Medicine,
University of Hawaii
USA

Robert L Balster PhD
Butler Professor of Pharmacology and Toxicology
Research Professor of Psychology and Psychiatry
Co-Director, Center for the Study of Tobacco Products
Virginia Commonwealth University
Richmond, VA
USA

Joaquin Barnoya MD
Research Director
Unidad de Cirugía Cardiovascular de Guatemala
Guatemala

Robert Beaglehole MD
Professor Emeritus
University of Auckland
Chair, Lancet NCD Action Group
New Zealand

Jay E Berkelhamer MD FAAP
Adjunct Professor of Pediatrics, Emory University School of Medicine
Adjunct Clinical Professor of Pediatrics
Morehouse College of Medicine Past President (2006-2007)
American Academy of Pediatrics
USA
Dr Mitchel Blair  
Officer for Health Promotion  
Royal College of Paediatrics and Child Health  
United Kingdom

Ruth Bonita MPH PhD MD (hon)  
Emeritus Professor  
University of Auckland  
New Zealand

Helmut Brand  
Jean Monnet Professor in European Public Health  
Head of the Department of International Health  
President EHFG (European Health Forum Gastein)  
Past President ASPHER (Association of Schools of Public Health in the European Region)  
Maastricht University  
The Netherlands

Professor Sir Harry Burns  
Prof of Global Health  
University of Strathclyde  
Former Scottish Chief Medical Officer  
United Kingdom

Professor Reinhard Busse  
Technical University Berlin  
Germany

Simon Capewell MD DSc  
Professor of Clinical Epidemiology  
University of Liverpool  
Department of Public Health & Policy,  
Institute of Psychology, Health & Society.  
United Kingdom

Dr Hilary Cass  
President  
Royal College of Paediatrics and Child Health  
United Kingdom
Frank J Chaloupka PhD
Distinguished Professor of Economics and Public Health
Director, Health Policy Center
University of Illinois at Chicago
USA

Simon Chapman AO PhD FASSA HonFFPH (UK)
Professor
Sydney School of Public Health
University of Sydney
Emeritus Editor, Tobacco Control
Australia

Prof Luke Clancy BSc MB MD PhD FRCPI FRCP (Edin) FFOMRCPI
Director General
TobaccoFree Research Institute
Ireland

Peter Cooper MD
Professor and Head
Department of Paediatrics
University of the Witwatersrand & Charlotte Maxeke Johannesburg Academic Hospital
Treasurer and Member of Executive Committee, International Pediatric Association
South Africa

Professor Elif Dagli
Pediatric Pulmonologist, Turkey
Chair, Health Institute Association, Turkey
Chair, Pediatric Pulmonology Society, Turkey
Past Chair, National Coalition on Tobacco or Health
Turkey

Professor Mike Daube AO
Professor of Health Policy and Director, Public Health Advocacy Institute
Curtin University, Perth
President, Australian Council on Smoking and Health
Australia

Sean P David MD SM DPhil
Clinical Associate Professor of Family & Community Medicine
Division of General Medical Disciplines
Stanford University School of Medicine
USA
Marisa de Andrade PhD
Impact Research Fellow
Stirling Management School
Institute for Social Marketing
University of Stirling
United Kingdom

Pascal Diethelm MSc
President, OxyRomandie
Geneva
Switzerland

Peter Donnelly MD
Professor of Public Health Medicine
University of St Andrews
Former Deputy Chief Medical Officer, Scottish Government
United Kingdom

Thomas Eissenberg PhD
Professor of Psychology and Co-director
Center for the Study of Tobacco Products
Virginia Commonwealth University
USA

Esteve Fernández MD PhD
Head, Tobacco Control Unit, Catalan Institute of Oncology/ Bellvitge Institute of Biomedical Research - ICO-IDIBELL
Associate Professor of Epidemiology and Public Health, University of Barcelona
Spain

Valeska C Figueiredo MD PhD
Center for Studies on Tobacco and Health
National School of Public Health
Fiocruz Foundation
Brazil

Sharon Fonn MBCh DOH DEpi FFCH PhD MASSAf
Professor
School of Public Health, University of the Witwatersrand, Johannesburg
Co-director Consortium for Advanced Research Training in Africa
Vice President Association of Schools of Public Health in Africa
South Africa
Becky Freeman PhD
Research Fellow
School of Public Health
University of Sydney
Australia

Karine Gallopel-Morvan PhD
Professeure des Universités - Marketing social
Professor - Social marketing
Equipe de recherche Management des Organisations de Santé (MOS)
Institut du Management
Rennes
France

Stanton A Glantz PhD
Professor of Medicine
American Legacy Foundation Distinguished Professor of Tobacco Control
Director, Center for Tobacco Control Research and Education
Director, WHO Collaborating Centre on Tobacco Control
University of California, San Francisco
USA

Professor Dr Helmut Gohlke MD FESC FACC
Chairman of the taskforce of cardiovascular prevention
German Cardiac Society
Ballrechten/Dottingen
Germany

Mark Gottlieb
Executive Director
Public Health Advocacy Institute
at Northeastern University School of Law
Boston MA
USA

Prakash C Gupta
Director
Healis - Sekhsaria Institute for Public Health
India

Sir Andy Haines MD
Professor of Public Health and Primary Care
London School Of Hygiene & Tropical Medicine
United Kingdom

**Bonnie Halpern-Felsher PhD FSAHM**
Professor of Pediatrics  
Director of Research  
Associate Director, Adolescent Medicine Fellowship Program  
Division of Adolescent Medicine, Department of Pediatrics  
Stanford University  
USA

**Professor Gerard Hastings OBE**
The Institute for Social Marketing  
University of Stirling, the Open University and  
L’École des Hautes Etudes en Santé Publique  
Stirling  
United Kingdom

**Professor Dr Reiner Hanewinkel**
Director  
Institute for Therapy and Health Research,  
Kiel  
Germany

**Todd Harper**
Chief Executive Officer  
Cancer Council Victoria  
Australia

**Norbert Hirschhorn MD**
In-Kind Consultant, Faculty of Health Sciences Tobacco Control Research Group  
American University of Beirut  
Lebanon

**Janet Hoek PhD**
University of Otago  
New Zealand

**Winthrop Professor C. D’Arcy J Holman AM**
Chair in Public Health  
School of Population Health  
University of Western Australia  
Australia
Dr Zulkifli Ismail MD
President, Asia Pacific Pediatric Association (APPA)
Past President, Malaysian Paediatric Association (MPA)
Malaysia

Robert K Jackler, MD
Sewall Professor and Chair
Otolaryngology-Head & Neck Surgery
Director, Stanford Research Into the Impact of Tobacco Advertising
Stanford University School of Medicine
USA

Professor Staffan Janson MD
Department of Public Health
Karlstad University
Karlstad
Sweden

William J Keenan, MD
Executive Director
International Pediatric Association
USA

Jonathan D Klein MD MPH FAAP
Director, Secretariat, NCD Child
Chair, Technical Assistance Group on NCDs, International Pediatric Association
Associate Executive Director, American Academy of Pediatrics
USA

J Randy Koch PhD
Executive Director
Institute for Drug and Alcohol Studies
Assoc. Professor, Family Medicine and Population Health
Virginia Commonwealth University
Richmond, VA
USA

Prof Andreas Konstantopoulos MD
President, International Pediatric Association (IPA)
Greece
Colleen A Kraft MD FAAP
Professor of Pediatrics
Virginia Tech Carilion School of Medicine and Research Institute
Chair of the Richmond Center Advisory Committee
USA

Professor Dr M Tezer Kutluk, MD PhD
Department of Pediatrics, Division of Pediatric Oncology
Hacettepe University Faculty of Medicine & Cancer Institute
President, National Coalition on Tobacco or Health, Turkey
Immediate Past President, European Cancer Leagues, Brussels
Past President, Turkish Association for Cancer Research and Control
Turkey

Professor Dr med Ulrich Laaser DTM&H MPH
Section of International Public Health (S-IPH)
Faculty of Health Sciences
University of Bielefeld
Germany

Harry A Lando PhD
Distinguished International Professor
University of Minnesota
USA

Professor Stephen Leeder AO
Emeritus Professor of Public Health and Community Medicine
Menzies Centre for Health Policy and School of Public Health
University of Sydney
Editor-in-Chief, Medical Journal of Australia
Australia

Simon Lenton
Co-Chair
British Association of Child and Adolescent Public Health (BACAPH)
United Kingdom

Professor Alastair H Leyland
Associate Director
MRC/CSO Social and Public Health Sciences Unit
University of Glasgow
United Kingdom
Pamela Ling MD MPH
Associate Professor of Medicine
Associate Director, Center for Tobacco Control Research and Education
University of California San Francisco
USA

Robert Loddenkemper MD FCCP
Former Chief of Department of Pneumology
Lungenklinik Heckeshorn
Berlin/Germany
Professor Emeritus of Charité University Medicine Berlin
Past-President of the European Respiratory Society
Germany

Alan D Lopez PhD
University of Melbourne Laureate Professor
Rowden-White Chair of Global Health and Burden of Disease Measurement
Director, Global Burden of Disease Group
Melbourne School of Population and Global Health
University of Melbourne
Former Chief epidemiologist, WHO’s Tobacco or Health Program (1992-1996)
Former Head, WHO Program on Substance Abuse (1996-1998)
Australia

Professor Dr Johan P Mackenbach
Department of Public Health
Erasmus MC
Rotterdam
The Netherlands

Ruth E Malone RN PhD FAAN
Professor and Chair, Department of Social and Behavioral Sciences
Nursing Alumni/Mary Harms Endowed Chair
School of Nursing
University of California, San Francisco
Editor-in-Chief, Tobacco Control
USA

Professor Julian Mamo MD MSc PhD MFPH(UK)
Head, Department Public Health
Faculty of Medicine & Surgery
University of Malta
Malta

Jose Maria Martin- Moreno MD PhD
Professor of Preventive Medicine and Public Health
University of Valencia
Spain

Bongani M Mayosi DPhil FCP(SA)
Professor and Head
Department of Medicine
Groote Schuur Hospital & University of Cape Town
Cape Town
South Africa

Wasim Maziak MD PhD
Professor and Chair, Department of Epidemiology
Robert Stempel College of Public Health and Social Work
Florida International University, Miami, Florida
Director, Syrian Center for Tobacco Studies
USA

Jim McCambridge PhD
Senior Lecturer in Behaviour Change
Faculty of Public Health & Policy
London School of Hygiene & Tropical Medicine
United Kingdom

Professor Martin McKee CBE
European Centre on Health of Societies in Transition
London School of Hygiene and Tropical Medicine
United Kingdom

Raúl Mejía MD
Investigador Titular
Centro de Estudios de Estado y Sociedad
Buenos Aires
Argentina

José Pereira Miguel MD PhD
Full Professor of Preventive Medicine and Public Health
Faculty of Medicine
University of Lisbon
Portugal
Rob Moodie AM MBBS MPH FAFPHM FRACGP DTMH
Professor of Public Health
University of Melbourne
Australia

Michael Moore
CEO Public Health Association of Australia
Vice President/President Elect World Federation of Public Health Associations
Australia

John F Murray MD FRCP
Professor Emeritus of Medicine
University of California San Francisco
USA

Rima Nakkash DrPH MPH
Assistant professor
Health Promotion and Community Health Department (WHO Collaborating Center on Health Promotion and Behavioural sciences)
Coordinator of the AUB Tobacco Control Research Group
American University of Beirut
Lebanon

Professor Dr Manfred Neuberger MD
Professor emeritus
Medical University of Vienna
Austria

Thomas E Novotny MD MPH
Professor of Global Health
Graduate School of Public Health
San Diego State University
Former Assistant Surgeon General, US Public Health Service
Former US Representative to the WHO Executive Board
USA

Professor Ian Olver AM MBBS MD PhD FRACP FACHPM AFRACMA
Medical Oncologist
Chief Executive Officer, Cancer Council Australia
Australia
Fred Paccaud MD MSc
Institute for Social and Preventive Medicine
University Hospital Center (CHUV)
Lausanne
Switzerland

Alexander A Padilla
President and CEO, PHILHEALTH
Philippine Health Insurance Corporation
The Philippines

Cheryl L Perry PhD
Professor and Regional Dean
The Rockwell Distinguished Chair in Society and Health
University of Texas School of Public Health
Austin Regional Campus
USA

Michael Pertschuk
Former Chairman, US Federal Trade Commission
Former Co-Director, The Advocacy Institute
USA

John P Pierce PhD
Distinguished Professor in Cancer Prevention
Department of Family and Preventive Medicine
Director, Population Sciences Division
Moores Cancer Center
University of California, San Diego
USA

Professor Allyson Pollock
Prof Public Health Research and Policy
Queen Mary, University of London
United Kingdom

Dr Martina Pötschke-Langer MD MA
Head of Unit Cancer Prevention and of
WHO Collaborating Centre for Tobacco Control
German Cancer Research Center (DKFZ)
Heidelberg
Germany
Robert N Proctor PhD
Professor of the History of Science and
Professor, by courtesy, of Pulmonary and Critical Care Medicine
Stanford University
USA

Professor Pekka Puska
Ex Director General
Terveyden ja hyvinvoinnin laitos – National Institute for Health and Welfare (THL)
Helsinki
Finland

K Srinath Reddy MD DM MSc DSc (Honoris Causa) DLitt (Honoris Causa)
President, Public Health Foundation of India
President, World Heart Federation
India

Dr Maria de Fátima Reis
Professor of Environmental Health
Faculty of Medicine
University of Lisbon.
Portugal

James Repace MSc
Repace Associates, Inc.
Secondhand Smoke Consultants
USA

Professor Juan M Rey-Pino
Associate Professor
Department of Marketing Research and Management
University of Granada
Spain

Professor Walter Ricciardi
Director of the Department of Public Health
Deputy Head (2010 - 2014) of the Faculty of Medicine "A. Gemelli"
Catholic University of the Sacred Heart
Rome
Italy
Ms Bungon Ritthiphakdee
Director
Southeast Asia Tobacco Control Alliance (SEATCA)
Thailand

Dr Harry Rutter
London School of Hygiene and Tropical Medicine
United Kingdom

Maria Victoria Salgado MD
Family Medicine Resident
Hospital Italiano de Buenos Aires
Argentina

Dr Yussuf Saloojee
Executive Director
National Council Against Smoking
South Africa

Professor Raul H Sansores MD
Departamento de Investigacion en Tabaquismo
Director, Smoking Cessation Program
National Institute of Respiratory Diseases
Mexico

Linda Sarna PhD RN FAAN
Professor and Lulu Wolf Hassenplug Endowed Chair
Immediate Past Chair, Academic Senate
UCLA School of Nursing
Los Angeles, California
USA

Dean E Schraufnagel MD
Professor
Pulmonary, Critical Care, Sleep, and Allergy
Depart of Medicine M/C 719
University of Illinois at Chicago
USA
**Dr Dr hc Rolf Schulte-Hermann**  
Professor of Toxicology  
EUROPEAN Registered Toxicologist (ERT)  
Former Director, Institute of Cancer Research,  
Head, Unit Chemical Safety and Cancer Prevention  
Medical University of Vienna  
Austria

**Alan Shihadeh**  
Professor, Department of Mechanical Engineering  
Principal Investigator, Aerosol Research Lab  
American University of Beirut  
Beirut  
Lebanon  
Project Director  
Center for the Study of Tobacco Products  
Virginia Commonwealth University  
Richmond, Virginia  
USA

**Associate Prof Freddy Sitas DPhil**  
Director, Cancer Research Division  
Cancer Council NSW  
Australia

**Bernard W Stewart PhD FRACI DipLaw**  
Professor  
School of Women’s and Children’s Health, UNSW and  
Head,  
Cancer Control Program  
South East Sydney Public Health Unit  
Australia

**Maurice G Swanson**  
Chief Executive  
National Heart Foundation of Australia, WA Division  
Deputy Chair,  
Cancer Council Australia and National Heart Foundation of Australia Tobacco Issues Committee  
Australia

**Dr Naveen Thacker MD**  
President Elect Asia Pacific Pediatric Association  
India
Associate Professor Samantha Thomas
Principal Research Fellow Public Health
School of Health and Society
Faculty of Social Sciences
University of Wollongong
Australia

TH Tulchinsky MD MPH
Emeritus Professor, Braun School Public Health, Hebrew University-Hadassah, Ein Karem, Jerusalem, Israel
Deputy Editor, Public Health Reviews, EHESP, Paris
Israel

Silvana Rubano B Turci
Centro de Estudos sobre Tabaco e Saúde da Escola Nacional de Saúde Pública da Fundação Oswaldo Cruz (CETAB/ENSP/Fiocruz)
Brazil

Professor Prakit Vathesatogkit MD ABIM FRCP (T) FRCP
Secretary-General, ASH Thailand
Thailand

Vasiliy V Vlassov MD
President,
Russian Society for Evidence Based Medicine
Russian Federation

Professor Melanie Wakefield PhD FASSA
Director and NHMRC Principal Research Fellow
Centre for Behavioural Research in Cancer
Cancer Council Victoria
Melbourne
Australia

Professor Kenneth D Ward PhD
Professor and Director, Division of Social and Behavioral Sciences
School of Public Health
The University of Memphis
USA
Professor Alan White  
Centre for Men's Health, Institute for Health & Wellbeing  
Leeds Metropolitan University  
United Kingdom

Martin White MD FFPH  
Professor of Public Health, Institute of Health & Society, Newcastle University  
Director, Fuse - UKCRC Centre for Translational Research in Public Health  
United Kingdom

Prof Friedrich J Wiebel  
formerly Institute of Toxicology  
German Research Center for Environmental Health, Neuherberg/Muenchen  
Germany

James Wiley MD  
Founder and chairman  
Focus Pediatrics, Mobile, AL  
USA

Dr Ingrid Wolfe  
Child Public Health Research Fellow  
London School of Hygiene and Tropical Medicine  
United Kingdom

Dr Salim Yusuf  DPhil  FRCPC  FRSC  OC  
Professor of Medicine, McMaster University  
Executive Director, Population Health Research Institute  
McMaster University, Hamilton Health Sciences  
Vice President Research, Hamilton Health Sciences  
Heart and Stroke Foundation/Marion W. Burke Chair in Cardiovascular Disease  
President Elect, World Heart Federation  
Canada

1 http://www.who.int/entity/tobacco/communications/statements/eletronic_cigarettes/en/index.html
2 http://nicotinepolicy.net/n-s-p/1751-statement-who-052014
3 Peeters S, Gilmore AB. Understanding the emergence of the tobacco industry's use of the term tobacco harm reduction in order to inform public health policy. Tob Control. 2014 Jan 22. doi: 10.1136/tobaccocontrol-2013-051502.
5 http://blog.euromonitor.com/2012/11/e-cigarettes-a-us2-billion-global-industry-who-should-be-worried.html
6 http://www.who.int/fctc/guidelines/article_5_3.pdf?ua=1
10 McCarthy M. E-cigarette companies target youth, US congressional study finds. BMJ. 2014 Apr 22;348:g2871. doi: 10.1136/bmj.g2871.
11 Legacy. Vaporized: E-Cigarettes, Advertising, And Youth. May 2014
15 Lee S, Grana RA, Glantz SA. Electronic cigarette use among Korean adolescents: a cross-sectional study of market penetration, dual use, and relationship to quit attempts and former smoking.
21 ibid.
27 Choi K, Forster JL. Response to Letter to the Editor Regarding “Beliefs and Experimentation with Electronic Cigarettes: A Prospective Analysis Among Young Adults.” Am J Prev Med
28 See reference #20.

Ibid


